The impact of race on outcome has been identified in a number of cancers, with African Americans having poorer survival compared with whites. We conducted a study to investigate the association of race with allogeneic hematopoietic cell transplant (HCT) outcomes. We identified 789 patients (58 African Americans and 731 whites) who underwent allogeneic HCT for hematologic disorders. There were no significant differences between African Americans and white patients in gender, performance status or comorbidity score. However, African Americans were younger than whites (median 40 years versus 47 years, P = 0.003) and were more likely to be in remission at HCT (74% versus 57%, P = 0.011), to have an HLA-mismatched donor (36% versus 14%, P o 0.001), to have positive donor or recipient CMV serostatus (90% versus 69%, P o 0.001) and to have received a cord blood transplant (21% versus 6%, Po 0.001). In univariate analysis, African Americans had worse overall survival (OS) (HR 1.41, P = 0.026) compared with whites, with no significant differences in acute or chronic GvHD, non-CMV infection or relapse. However, after adjusting for several transplant and disease-related factors in multivariate analysis, the OS difference between African Americans and whites became nonsignificant (HR 1.27, P = 0.18). These results suggest that race in and of itself does not lead to worse survival post HCT.
INTRODUCTION
Racial differences have been cited in a number of cancers, with African Americans having shorter overall survival (OS) compared with whites in head and neck, colon, prostate, endometrial and breast cancers. [1] [2] [3] [4] [5] [6] [7] Several reasons have been suggested, including socieoeconomic and cultural factors, cancer biology, differential treatment intensity, pharmacogenetics and comorbid conditions. [8] [9] [10] [11] [12] Data from hematologic malignancies such as AML also demonstrate poorer survival and worse CR rates in African Americans, specifically men, compared with African American women and whites. 13 A subsequent study did not find any significant differences in the type or intensity of post-remission therapy after AML induction. Although noting a significant delay in starting post-remission therapy, this did not ultimately affect overall survival.
14 Differences in procedure choice for a variety of medical conditions, including malignancies, have also been associated with race, ethnicity and other socio-demographic factors. [15] [16] [17] [18] [19] [20] [21] Allogeneic hematopoietic cell transplantation (HCT) is a procedure that offers the only potentially curative treatment for many patients with hematologic malignancies. It has been previously reported, however, that racial and ethnic minorities who received HCT have worse survival when compared with whites. [22] [23] [24] Although several potential reasons have been postulated as above, there remain insufficient data to explain the racial differences in outcome after HCT. We thus undertook this retrospective analysis at our center to study the race-related survival after HCT in hopes of better identifying potential prognostic factors to account for poor outcome.
MATERIALS AND METHODS
We identified a total of 789 consecutive patients who underwent allogeneic HCT for malignant and nonmalignant hematologic diseases from January 1997 through December 2011 at the Cleveland Clinic Taussig Cancer Institute. Race was self-reported by patients and obtained from registration data in the electronic medical record, and verified by data from notes obtained from our social workers. Data collected included patient demographics such as age and gender, and disease and transplant characteristics, including diagnosis, disease status, HCT comorbidity index, hematopoietic cell source, preparative regimen and CMV status. This retrospective analysis was approved by the institutional review board.
Disease status at the time of transplantation was classified as active and in remission as per standard criteria. Comorbidities were scored according to the HCT-specific index, and severity was graded as low (score 0), intermediate (score [1] [2] or high (score ⩾ 3) as previously defined. 25 Neutrophil and platelet engraftment was defined as the first of 3 consecutive days with an ANC ⩾ 0.5 × 10 9 /L and the first of 7 days of platelet counts ⩾ 20 × 10 9 /L without transfusion. The diagnosis of GvHD was based on clinical criteria with histopathologic confirmation whenever possible. The severity of acute and chronic GvHD was graded according to previously defined criteria. [26] [27] [28] Because of the time period and retrospective nature of this analysis, chronic GvHD was graded on the basis of revised Seattle classifications of limited and extensive chronic GvHD. 28 This was a retrospective study evaluating the effect of race on transplant and disease-related outcomes in patients undergoing allogeneic HCT. The end points analyzed were incidence of CMV infection, non-CMV infection, acute GvHD, chronic GvHD, relapse, relapse mortality (RM), non-RM, OS and relapse-free survival (RFS). OS and RFS were estimated using the Kaplan-Meier method and compared between races using the log-rank test. All other outcomes were estimated using the cumulative incidence method and compared using the Gray test. Cox proportional hazards analysis was used to assess univariable prognostic factors for OS and RFS.
Stepwise Cox analysis with a variable entry criterion of P ⩽ 0.10 and a variable retention criterion of P ⩽ 0.05 was used to identify multivariable prognostic factors. To confirm multivariate findings, propensity analysis was also performed to identify a group of white patients who were wellmatched with African Americans on the basis of all baseline characteristics (gender, age, KPS, number of prior chemotherapy regimens, prior radiation therapy, diagnosis (myeloid, lymphoid or other), months from diagnosis to transplant, disease status at transplant, donor relationship, HLA match, CMV serostatus, transplant type, cell source and dose). Matches were found for 47 of the 58 African American patients. Outcomes were compared between the well-matched groups, removing baseline differences that may confound outcomes. All statistical analyses were performed with SAS version 9.2 (SAS Institute, Cary, NC, USA).
RESULTS

Patient and transplant characteristics
This study analyzed 58 African Americans and 731 white (nonHispanic) patients who underwent allogeneic HCT. Median time of follow-up among living patients was 56 months (range, 6-183 months). Characteristics of African American and white patients are as described in Table 1 . Patients primarily underwent transplantation for AML (n = 304), ALL (n = 107), myelodysplastic syndrome (MDS) (n = 107), CML (n = 87) or non-Hodgkin's lymphoma (NHL) (n = 83). There were no significant differences between African American and white patients with regard to gender, performance status or comorbidity scores. However, African Americans were younger than whites, with a median of 40 years (range 18-62) compared with 47 years (range 18-71) (P = 0.003), and were more likely to be in remission at the time of HCT (74% compared with 57%, P = 0.011), to have an HLAmismatched donor (36% versus 14%, P o 0.001), to have positive donor or recipient CMV serostatus (90% versus 69%, P o 0.001) and to have a cord blood transplant (21% versus 6%, P o0.001).
Time from diagnosis to transplant was also longer in African Americans (median 11 months (range 2-137)) compared with whites (median 8 months (0.2-246)), with a trend toward significance (P = 0.06).
Hematopoietic recovery, infection and GvHD There were no significant differences in time to neutrophil (median 16 days (range 9-40) versus 15 days (range 1-77 days), P = 0.81) or platelet recovery (median 22 days (range 10-93) versus 22 days (range 4-239), P = 0.81) in African American compared with white patients. Length of initial transplant hospital stay also did not differ between African American and white transplant recipients (median 34 days (range 17-82) versus 33 days (range 10-148), P = 0.52, respectively). The cumulative incidence of non- 3 (6) 28 (4) HCT-CI (n = 54, 710) Low (0) 14 (26) 263 (37) (5) Abbreviations: ATG = anti-thymocyte globulin; CI = confidence interval; HL = Hodgkin lymphoma; HCT = hematopoietic cell transplantation; MDS = myelodysplastic syndrome; MMF = mycophenolate mofetil; MPN = myeloproliferative neoplasms; MTX = methotrexate; NHL = non-Hodgkin's lymphoma; PNH = paroxysmal nocturnal hemoglobinuria; PS = performance status.
Racial differences in Allo-HCT BK Hamilton et al CMV infections was similar between ethnic groups (71% African Americans and 68% whites at 1 year, P = 0.93). Incidence of CMV infections was significantly higher in African Americans (59% versus 34% in whites at 1 year, P o 0.001). GvHD prophylaxis was primarily a calcineurin inhibitor (tacrolimus or cyclosporine) in combination with mycophenolate mofetil or MTX. There were no significant differences in the cumulative incidence of grade 2-4 and grade 3-4 acute GvHD at 1 year between African American (50 and 21%) and white (44 and 18%) patients (P = 0.48 and P = 0.70, respectively) ( Figure 1a ). There was also no significant difference in the cumulative incidence of any chronic GvHD at 1 year (40% African Americans compared with 39% whites, P = 0.94) (Figure 1b ).
Relapse and survival
The two ethnic groups did not differ significantly in terms of relapse. Relapse at 5 years was 27% in the African American group compared with 32% in the white group (P = 0.34). The cumulative incidence of non-RM was higher in the African American group compared with the white group (5-year incidence 55% versus 42%) (P = 0.012). RFS and OS ( Figure 2 ) were also significantly worse (5-year RFS 22% versus 30%, P = 0.043; and OS 23% versus 35%, P = 0.025) in African Americans compared with whites. Cause of death was relapse in 26% (n = 12) of African Americans and 35%
(n = 165) of whites. Among the 34 African American and 306 white non-relapse deaths, causes of death were similar among the two groups-the most common being infection (20% and 18%, respectively), followed by acute (15 and 13%) and chronic (11 and 12%) GvHD.
Univariable and multivariable prognostic factors and propensity analysis for OS In univariable analysis, African American race, increased number of prior chemotherapy regimens, worse performance status, intermediate-or high-risk HCT comorbidity index, active disease at the time of transplant, unrelated donor, HLA mismatch and positive CMV serostatus were all significant risk factors for survival. In multivariable analysis, several of these factors remained significant. Number of prior chemotherapy regimens (HR 1.11, P = 0.001), Karnofsky performance status (HR 0.83, P o 0.001), HCT comorbidity index (HR 1.73, P o 0.001), disease status at the time of transplant (HR 1.75, P o 0.001) and HLA mismatch (HR 1.60, Po 0.001) were significant prognostic variables in the multivariable model. Interestingly, male gender became a significant prognostic factor (HR 1.24, P = 0.023), whereas African American race became nonsignificant (HR 1.27, P = 0.18) once the other variables were taken into account (Table 2) . Propensity analysis was used to identify a group of white patients who were well-matched with African Americans on the basis of all baseline characteristics. Matches for 47 of 58 African American patients were found, and among these well-matched patients the only outcome that differed between ethnic races was CMV infection, with African Americans having a statistically significantly higher incidence at 1 year (66% versus 30%, P o0.001). Among well-matched groups, OS and RFS were not significant (P = 0.92 ( Figure 2b ) and P = 0.43, respectively). Incidence of grade 2-4 acute GvHD at 6 months was higher in African Americans (55% versus 42%), but this was not significant (P = 0.38).
DISCUSSION
Previous studies have demonstrated variable survival differences after allogeneic HCT in African Americans compared with whites. 22, 23, [29] [30] [31] A study from the Fred Hutchinson Cancer Institute found poorer OS among African Americans compared with whites after HCT for hematologic and non-hematologic malignancies, primarily attributed to a higher risk of severe acute GvHD (37% African Americans versus 21% whites). 23 Their analysis also demonstrated increased time interval from diagnosis to transplantation among African Americans compared with whites, even among sibling donors, raising the possibility of delayed referral and resistance to referral to HCT. A matched cohort analysis found no association between socioeconomic factors and survival, however. A Center for International Blood and Marrow Transplant Research (CIBMTR) study evaluating race and socioeconomic status in unrelated donor HCT found inferior outcomes among African Americans that were not explained by HLA mismatch, worse GvHD or socioeconomic status. In contrast to the previous study, however, socioeconomic status in and of itself was found to be associated with worse unrelated donor HCT outcomes independent of race. 22 Another more recent study from the CIBMTR 31 also reported worse survival outcomes, attributed to more severe acute GvHD, among African Americans (29%) compared with whites (13%) undergoing HCT for aplastic anemia. In contrast, another large registry study demonstrated a difference in survival rates in Hispanics, but not in African Americans, compared with whites after allogeneic HCT for AML, ALL and CML. 30 A smaller study from our institution evaluating postremission therapy, which included allogeneic HCT, also did not find survival differences between African Americans and whites. 14 Our current analysis demonstrates important differences between racial populations undergoing allogeneic HCT, including CMV serostatus and having an HLA-matched donor. Despite these differences, we found that the African American race in and of itself did not translate into worse survival after accounting for other prognostic factors.
Although advances in monitoring and pre-emptive treatment have significantly improved the incidence and morbidity and mortality of CMV disease after allogeneic HCT, CMV infection remains a major complication after HCT, and OS continues to be associated with pre-transplant CMV serostatus of the patient. 32 Tissue-invasive CMV disease may be associated with increased risk of GvHD, 33 myelosuppression and other bacterial and fungal infections. 34 Anti-viral agents may be relatively effective in eradicating CMV infection. However, preventative strategies are under-utilized after HCT, given the adverse effects of therapies such as ganciclovir (myelosuppression) and foscarnet (renal failure and electrolyte abnormalities).
Several studies have previously established that race is a factor in CMV seroprevalence. African American adults have been found to have twice the prevalence of CMV infection compared with age-matched whites, 35, 36 and the rate of CMV seropositivity may approach 100% in some series. 37, 38 The reasons for the increased rate of CMV infections among African Americans compared with whites is not completely known, but demographic factors such as African American race, female gender and lower socioeconomic Racial differences in Allo-HCT BK Hamilton et al status have been suggested to be the markers for behaviors and environmental factors that facilitate CMV transmission, such as breast-feeding, childcare practices, sexual activity, larger family sizes or crowded living conditions. In our current cohort of patients, 90% of African Americans had donor or recipient CMV seropositivity, and were a high-risk group for development of CMV infection, with an incidence of nearly 60% at 1 year. The use of pre-emptive or prophylactic strategies in this high-risk population may thus warrant further study.
Despite the fact that we found that African Americans were younger than whites and more likely to be in remission at the time of transplant, the African American patient group had a longer time from diagnosis to transplant and were more likely to have an HLA-mismatched donor or cord blood transplant compared with whites. These differences indicate a lack of HLA-matched donors for African Americans, as has been previously reported. [39] [40] [41] According to data reported by the National Marrow Donor Program (NMDP), the likelihood of finding an HLA-A, -B, -C and -DRB1 high-resolution matched unrelated donor is 75% for whites, but only 19% for African Americans. 42 This difference is attributed not only to a smaller donor pool but also to a greater degree of HLA polymorphisms with large numbers of HLA haplotypes specific to blacks, as well as a higher donor attrition rate from the NMDP registry. Recent studies trying to identify barriers to blood and marrow donation among ethnic groups have demonstrated lack of awareness, distrust of the medical system, ambivalence and lack of understanding regarding cost and discomfort among some of the major barriers to donation. 40, 41 Further recruitment and education strategies are thus needed to overcome some of these barriers to donation.
Our current analysis was limited by the retrospective nature of the study and the relatively small number of patients (7%) belonging to the African American minority group. Although the percentage of African Americans among other ethnic groups varied significantly among recent transplant studies, 23, 31 this number is comparable to the larger CIBMTR studies 22, 30 as well as to past leukemia studies 13, 14 and indicative of our current leukemia/hematologic malignancy population. Despite this, we acknowledge that the absolute number of African Americans in this study is small, and, given this, the study may lack the power to detect significant racial differences. Although the magnitude of hazard ratio for race and gender was small, they were similar and, whereas gender was found to be a significant factor for survival on multivariable analysis, race was nonsignificant. Thus, the potential lack of statistical power to detect ethnic differences must be considered when interpreting the results of this study. There are also several unmeasured factors that may also contribute to lower survival rates in African Americans, such as socioeconomic status, insurance, compliance and genetic polymorphisms, which we were not able to take into account and are beyond the scope of this study. The potential for genetic differences in disease, response to treatment and HLA differences are thus important factors to be further studied. In contrast to previous studies, 23, 31 however, we did not find any significant differences in acute GvHD among African Americans and whites. This may be attributed to the fact that we used significantly more cord blood transplants (20% of our African American cohort) compared with mismatched unrelated donors in other studies. Although cord blood transplantation has been shown to lead to less acute GvHD, 43 it is also associated with delayed hematopoietic and immune recovery, which may lead to worse transplant-related mortality and survival. Given the significance of the use of cord blood transplants, we also evaluated racial outcomes by graft source (Supplementary  Table) . Although limited by the number of patients, a CIMBTR study evaluating the impact of race on umbilical cord blood transplants also revealed inferior survival for African Americans compared with whites. However, when adjusted for the size and HLA match of the cord blood units, survival difference by race became nonsignificant. 24 We further acknowledge a relatively higher rate of non-RM in this study (55% in African Americans and 42% for whites) than what is currently expected. Although umbilical cord blood transplants may have contributed to a higher incidence of non-RM, given the fact that our study spanned a time period from 1997 to 2011, we also hypothesize that many patients were transplanted in this earlier time period in which advances in supportive care were not yet implemented, and thus additionally may have contributed to the higher than expected TRM.
Nevertheless, our findings suggest that African American race in and of itself does not lead to worse survival post HCT. There are several measures, however, that can be taken to improve outcomes for African Americans, including the recruitment of HLA-matched African American donors and improving the identification of high-risk CMV-positive African American transplants.
